Loxo Oncol Drug Patent Portfolio
Loxo Oncol owns 1 orange book drug protected by 5 US patents Given below is the list of Loxo Oncol's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12109193 | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide | 14 Sep, 2041 | Active |
| US10342780 | Compounds useful as kinase inhibitors | 16 Dec, 2036 | Active |
| US10464905 | Compounds useful as kinase inhibitors | 16 Dec, 2036 | Active |
| US10695323 | Compounds useful as kinase inhibitors | 16 Dec, 2036 | Active |
| US10918622 | Compounds useful as kinase inhibitors | 16 Dec, 2036 | Active |
Latest Legal Activities on Loxo Oncol's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Loxo Oncol.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
|
Email Notification
Critical
| 14 May, 2024 | US10695323 |
| Mail Patent eCofC Notification | 14 May, 2024 | US10695323 |
| Patent eCofC Notification | 14 May, 2024 | US10695323 |
| Recordation of Patent eCertificate of Correction | 14 May, 2024 | US10695323 |
| Second letter to regulating agency to determine regulatory review period | 08 May, 2024 | US10342780 |
| Post Issue Communication - Certificate of Correction | 24 Apr, 2024 | US10695323 |
| Mail Certificate of Correction Memo | 23 Apr, 2024 | US10695323 |
| Certificate of Correction Memo | 18 Apr, 2024 | US10695323 |
| Letter from FDA or Dept of Agriculture re PTE application | 30 Jan, 2024 | US10342780 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 21 Nov, 2023 | US10695323 |
| RX - Mail Miscellaneous Communication to Applicant | 03 Aug, 2023 | US10918622 |
| Initial letter Re: PTE Application to regulating agency | 06 Jul, 2023 | US10342780 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Apr, 2023 | US10464905 |
| Patent Term Extension Application under 35 USC 156 Filed | 22 Mar, 2023 | US10342780 |
| Post Issue Communication - Certificate of Correction | 26 Jan, 2023 | US10918622 |
Loxo Oncol's Family Patents
Loxo Oncol Drug List
Given below is the complete list of Loxo Oncol's drugs and the patents protecting them.
1. Jaypirca
Jaypirca is protected by 5 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12109193 | Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1H-pyrazole-4-carboxamide |
14 Sep, 2041
(16 years from now)
| Active |
| US10342780 | Compounds useful as kinase inhibitors |
16 Dec, 2036
(12 years from now)
| Active |
| US10464905 | Compounds useful as kinase inhibitors |
16 Dec, 2036
(12 years from now)
| Active |
| US10695323 | Compounds useful as kinase inhibitors |
16 Dec, 2036
(12 years from now)
| Active |
| US10918622 | Compounds useful as kinase inhibitors |
16 Dec, 2036
(12 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Jaypirca's drug page